Understanding how older adults with acute myeloid leukemia age and respond to treatment
Official title: Aging trajectories and outcomes of older adults with acute myeloid leukemia
Funded at University of Nebraska Medical Center · NIH-10886813 · Data updated 2026-11-12
This study is looking at how new treatments for acute myeloid leukemia (AML) affect the thinking skills and daily lives of older adults, aiming to help them maintain their independence and improve their quality of life.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project start | July 12, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $489,655 |
| NIH project number | 5R37CA276928-02 |
| Project ID | NIH-10886813 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are older adults aged 60 and above who have been diagnosed with acute myeloid leukemia.
✕Less likely to help
Patients who are younger than 60 years or those with other significant health conditions that preclude participation in treatment may not benefit from this research.
What this research studies
This research investigates the aging trajectories and outcomes of older adults diagnosed with acute myeloid leukemia (AML), focusing on how new treatments, particularly a combination of venetoclax and low-intensity chemotherapy, affect cognitive function and daily living activities. The study aims to identify the risks of cognitive decline and loss of independence associated with these treatments, while also exploring factors that may influence these outcomes. By utilizing advanced techniques like electroencephalography (EEG), the research seeks to provide insights into the brain's activity in response to treatment. Ultimately, the goal is to improve the quality of life for older adults facing this challenging diagnosis.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies that enhance cognitive function and independence for older adults with acute myeloid leukemia.
How similar studies have gone: Previous research has shown promising results with similar treatment approaches in improving cognitive function and quality of life in older adults with hematological cancers.
Where this research is happening
-
University of Nebraska Medical Center
Omaha, United States Active
Researchers
- Principal investigator: Bhatt, Vijaya Raj — University of Nebraska Medical Center
- Study coordinator: Bhatt, Vijaya Raj
Related research
Other NIH-funded projects on the same topics.
-
Aging with AML: Understanding how venetoclax plus low-intensity therapy affects older adults
This project looks at how a newer AML treatment works for adults aged 60 and older, focusing on how it affects thinking, daily activities, and independence.
-
Understanding how older adults with acute myeloid leukemia fare with new treatments
This project looks at how new treatments for acute myeloid leukemia affect the daily lives and thinking abilities of older adults.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.